Welcome, Guest. Please login or register.
November 27, 2020, 09:50:22 pm

Login with username, password and session length


Members
  • Total Members: 6249
  • Latest: Sugar67
Stats
  • Total Posts: 55050
  • Total Topics: 4814
  • Online Today: 69
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 44
Total: 44

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Ocaliva Improves Liver Fibrosis in People With NASH  (Read 380 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 770
    • Hep Mag
Ocaliva Improves Liver Fibrosis in People With NASH
« on: April 14, 2020, 12:24:50 pm »
Ocaliva (obeticholic acid) significantly improved liver fibrosis related to non-alcoholic steatohepatitis (NASH), though it did not lead to NASH resolution, according to a recently published study. The medication is scheduled for a Food and Drug Administration (FDA) review in April 2020.

Zobair Younossi, MD, PhD, of Inova Fairfax Medical Campus in Falls Church, Virginia, and colleagues conducted the Phase III REGENERATE trial to evaluate Ocaliva, being developed by Intercept Pharmaceuticals, as a treatment for NASH. Interim results were published in The Lancet in December and presented at the 2019 International Liver Congress last April

“This study is a pivotal step for the development of drugs to treat NASH and is likely to be the first to receive regulatory approval,” wrote the authors of an editorial accompanying the study.

For more...
https://www.hepmag.com/article/ocaliva-improves-liver-fibrosis-people-nash

 


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.